首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

2102959

全球卒中流行病學分析與預測：2026 年

Global Stroke Epidemiology Analysis and Forecast, 2026

出版日期: 2026年07月21日 | 出版商:

Knowledge Sourcing Intelligence | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計在預測期內，全球中風患者人數將以 1.5% 的複合年成長率成長，從 2026 年的 9,880 萬增加到 2035 年的 1.128 億。

中風仍然是全球第二大死因和第三大致殘原因，其中大部分疾病負擔發生在低收入和中等收入國家。

中風包括缺血性中風、腦出血、蜘蛛膜下腔出血和短暫性腦缺血發作（TIA）。缺血性中風約佔全球整體所有中風病例的85%，一直是流行病學研究和治療研發的重點。流行病學分析能夠提供有關患者群體、人口分佈、疾病進展、死亡率趨勢、危險因素、醫療負擔和區域差異的寶貴信息，從而為製藥公司、醫療專業人員、研究人員和政策制定者提供戰略決策支持。

市場促進因素

全球中風負擔日益加重

由於人口老化、預期壽命延長、高血壓、糖尿病、肥胖、心房顫動、吸菸和久坐不動的生活方式等因素，中風病例數持續增加。儘管許多國家的年齡調整後發病率正在下降，但全球中風病例、死亡和倖存者的絕對數量仍在持續上升。

對人口健康數據的需求日益成長

醫療保健系統、製藥公司和公共衛生機構越來越依賴流行病學數據來改善疾病監測、分配醫療保健資源、識別高風險族群以及支持臨床研究和打入市場策略。

中風預防計畫擴展

各國政府和醫療機構持續投資於高血壓管理、糖尿病管理、戒菸支持、健康生活方式推廣和早期診斷項目，旨在降低中風率並改善長期預後。

加大對神經學研究的投入

隨著以預防中風、早期診斷、精準醫療和復健為重點的研究活動活性化，對高品質流行病學資料集的需求持續成長，以支持臨床開發和醫療保健政策。

區域趨勢

在北美，廣泛的流行病學監測得以維持，這得益於完善的卒中登記系統、先進的醫療基礎設施以及普及的影像診斷服務。急性中風治療的持續改進，使得中風死亡率下降，長期生存者人數增加。

歐洲持續受益於已建立的國家中風登記系統、協調一致的預防計畫和強力的公共衛生措施。儘管人口老化導致絕對病例數增加，但一些歐洲國家的年齡已調整的中風發生率卻呈下降趨勢。

亞太地區人口眾多且老化嚴重，是全球中風患者人數最多的地區之一。儘管中國、印度和日本對該地區的疾病負擔貢獻顯著，但快速的都市化和心血管危險因子的增加仍在持續推動新中風病例的增加。

在拉丁美洲、中東和非洲，由於人口結構變化、心血管危險因子的增加以及診斷技術的進步，中風發病率持續上升。預計對醫療保健領域的持續投資將加強全部區域的流行病學監測和疾病管理。

本報告調查了中風流行病學分析的全球趨勢，總結了疾病和流行病學分析、市場影響因素、創新和研發趨勢、流行病學分析的市場規模趨勢和預測、按各個細分市場和地區進行的詳細分析、相關法規和政策、競爭格局以及主要公司的概況。

中風：概述
中風的分類
病因和病理生理學
流行病學分析
- 全球發病率分析
- 全球盛行率分析
- 特定年齡流行病學
- 性別流行病學
- 按亞型分類的中風流行病學
- 死亡率分析
- 失能調整後存活年（DALYs）
- 復發率分析
- 流行病學預測

第3章市場動態

市場概覽
市場促進因素
市場限制因素
市場機遇
波特五力分析
PESTLE分析
價值鏈分析

第4章商業化與市場進入

市場進入概覽
還款系統狀態
醫療科技評估趨勢
價格分析
病人准入計劃
保險覆蓋範圍趨勢
相關利益者分析

第5章：創新與通路展望

創新概覽
新興技術
- 人工智慧輔助中風檢測
- 數位療法
- 高級神經影像學
- 穿戴式監測設備
管道狀態
- 第一階段候選藥物
- 二期管道候選藥物
- 三期管道候選藥物
管道分析：按作用機制分析
管道分析：按模式
- 小分子藥物
- 生物製藥
- 細胞療法
- 基因治療
臨床試驗現狀
專利分析
投資和資金籌措趨勢

第6章當前治療狀況

目前治療模式
急性中風管理
- 靜脈溶栓治療
- 機械血栓切除術
- 手術介入
二級預防中風
- 抗血小板治療
- 抗凝血治療
- 降血脂治療
- 血壓管理
復健和長期護理
治療指南和臨床實踐趨勢

第7章全球卒中流行病學報告：市場規模與預測

全球市場概覽
歷史市場規模分析
市場預測
市場魅力分析
更多發展機會

第8章：全球卒中流行病學報告：細分市場分析

按類型描邊
- 缺血性中風
- 出血性中風
- 短暫性腦缺血發作（TIA）
- 其他
依藥物類型
- 溶栓藥物
- 抗血小板藥物
- 抗凝血劑
- 抗高血壓藥物
- 其他
治療類型
- 靜脈注射藥物
- 血管內治療
- 外科手術
基於嚴重程度
- 溫和的
- 緩和
- 嚴重
按年齡層
- 20歲以下
- 20-50歲
- 50-70歲
- 70歲以上
最終用戶
- 醫院
- 專科診所
- 復健中心
- 其他

第9章區域分析

北美洲
歐洲
亞太地區
拉丁美洲
中東和非洲
- 市場規模和成長
- 流行病學趨勢
- 監管概述
- 競爭強度

第10章：主要國家分析

加拿大
德國
中國
日本
印度

第11章法規與政策概述

監管概述
美國法律規範（FDA）
歐洲法律規範（EMA）
日本法律規範（藥品和醫療設備管理局）
印度的法律規範（CDSCO）
中國的法律規範（NMPA）
臨床試驗條例
藥物核准途徑
藥物安全監測要求
影響中風管理的醫療保健政策

第12章競爭格局

市佔率分析
競爭性標竿分析
戰略部署
SWOT分析
競爭定位矩陣

第13章：公司簡介

Genentech
Boehringer Ingelheim
F. Hoffmann-La Roche Ltd
Novartis AG
Bayer AG
Johnson & Johnson
Daiichi Sankyo
Sanofi
Novo Nordisk
AstraZeneca PLC
Merck & Co., Inc.
GlaxoSmithKline plc
Eli Lilly and Company
AbbVie Inc.

第14章未來展望

未來流行病學趨勢
新療法的創新
未來監理趨勢
數位醫療和人工智慧的影響
市場預測情景
策略建議

第15章：調查方法

簡介目錄

Product Code: KSI-008957

The global stroke prevelance is projected to grow at a CAGR of 1.5% during the forecast period, increasing from USD 98.8 million patients in 2026 to USD 112.8 million patients by 2035.

Stroke remains the second leading cause of death and the third leading cause of disability worldwide, with the majority of the disease burden occurring in low- and middle-income countries.

Stroke encompasses ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, and transient ischemic attack (TIA). Ischemic stroke accounts for nearly 85% of all stroke cases globally and remains the primary focus of epidemiological research and therapeutic development. Epidemiology analysis provides valuable insights into patient populations, demographic distribution, disease progression, mortality trends, risk factors, healthcare burden, and regional variations that support strategic decision-making for pharmaceutical companies, healthcare providers, researchers, and policymakers.

Market Drivers

Increasing Global Burden of Stroke

The number of stroke cases continues to rise because of population aging, increasing life expectancy, hypertension, diabetes, obesity, atrial fibrillation, smoking, and sedentary lifestyles. Although age-standardized rates have declined in many countries, the absolute number of stroke cases, deaths, and survivors continues to increase worldwide.

Growing Need for Population Health Data

Healthcare systems, pharmaceutical companies, and public health organizations increasingly rely on epidemiological data to improve disease surveillance, allocate healthcare resources, identify high-risk populations, and support clinical research and market access strategies.

Expansion of Stroke Prevention Programs

Governments and healthcare organizations continue investing in hypertension control, diabetes management, smoking cessation, healthy lifestyle promotion, and early diagnosis programs aimed at reducing stroke incidence and improving long-term outcomes.

Rising Investment in Neurological Research

Growing research activity focused on stroke prevention, early diagnosis, precision medicine, and rehabilitation continues to increase demand for high-quality epidemiological datasets supporting clinical development and healthcare policy.

Market Restraints

Underdiagnosis in Developing Countries

Limited access to neurological care, inadequate diagnostic infrastructure, and inconsistent disease reporting contribute to underestimation of stroke prevalence in several low- and middle-income countries.

Variability in Data Collection

Differences in national registries, healthcare systems, disease classification, and surveillance methodologies create variability in epidemiological estimates across regions.

Healthcare Access Disparities

Socioeconomic inequalities continue to influence diagnosis rates, treatment access, rehabilitation services, and survival outcomes, particularly in resource-limited settings.

Epidemiology Insights

The global stroke epidemiology can be segmented by stroke type, age group, gender, risk factor, disease severity, and geography.

By stroke type, the epidemiology includes ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, and transient ischemic attack (TIA). Ischemic stroke represents the largest proportion of diagnosed cases worldwide, while hemorrhagic stroke contributes disproportionately to mortality despite its lower incidence.

By age group, stroke incidence increases substantially with advancing age. Adults aged 65 years and older account for the largest patient population, although the incidence of stroke among younger adults is gradually increasing because of obesity, diabetes, hypertension, and lifestyle-related risk factors.

By gender, stroke affects both men and women, with incidence generally higher among men at younger ages, while women experience a greater lifetime risk because of longer life expectancy and age-related disease burden. Women also account for a substantial proportion of stroke-related mortality in older age groups.

By risk factor, major contributors include hypertension, diabetes mellitus, atrial fibrillation, dyslipidemia, obesity, smoking, excessive alcohol consumption, physical inactivity, unhealthy diet, and environmental exposures. Hypertension remains the single most important modifiable risk factor for stroke worldwide.

Geographically, epidemiological analysis evaluates disease burden across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, highlighting differences in incidence, prevalence, mortality, disability-adjusted life years (DALYs), healthcare access, and treatment availability.

Epidemiological Trends

The global stroke epidemiology continues to evolve because of demographic and lifestyle changes.

Key trends include:

Increasing absolute number of stroke cases worldwide.
Growing prevalence among aging populations.
Rising incidence associated with hypertension, diabetes, and obesity.
Greater disease burden in low- and middle-income countries.
Improved survival resulting in higher numbers of stroke survivors requiring long-term care.
Increasing use of national stroke registries and real-world epidemiological databases.
Expansion of precision epidemiology through artificial intelligence and digital health technologies.

Regional Insights

North America maintains extensive epidemiological surveillance supported by comprehensive stroke registries, advanced healthcare infrastructure, and widespread access to diagnostic imaging. Continued improvements in acute stroke care have reduced mortality while increasing the number of long-term stroke survivors.

Europe continues to benefit from established national stroke registries, coordinated prevention programs, and strong public health initiatives. Several European countries have reported declining age-standardized stroke rates despite increasing absolute case numbers due to population aging.

Asia-Pacific accounts for one of the largest global stroke populations because of its large and aging population base. China, India, and Japan contribute significantly to the regional disease burden, while rapid urbanization and increasing cardiovascular risk factors continue to drive new stroke cases.

Latin America and the Middle East & Africa continue to experience increasing stroke incidence because of demographic transition, expanding cardiovascular risk factors, and improving diagnosis. Continued healthcare investment is expected to enhance epidemiological surveillance and disease management across these regions.

Competitive Landscape

The stroke epidemiology landscape involves healthcare organizations, epidemiology research firms, academic institutions, government agencies, pharmaceutical companies, and public health organizations.

Organizations continue investing in large-scale population studies, disease registries, real-world evidence, artificial intelligence-assisted analytics, and longitudinal epidemiological databases. Strategic collaborations between academic institutions, healthcare providers, pharmaceutical companies, and government agencies continue to improve understanding of stroke burden and support clinical development.

Future Outlook

The future of stroke epidemiology analysis will be driven by advances in digital health, artificial intelligence, precision medicine, genomic epidemiology, and real-world evidence generation. Improved disease surveillance, standardized reporting systems, and integration of electronic health records will provide more accurate estimates of stroke incidence, prevalence, mortality, and long-term outcomes.

Increasing global collaboration, expanded national stroke registries, and improved access to healthcare data are expected to strengthen epidemiological research while supporting prevention programs, therapeutic innovation, and healthcare resource planning through 2035.

Conclusion

The Global Stroke Epidemiology Analysis demonstrates the growing worldwide burden of stroke driven by aging populations, increasing cardiovascular risk factors, and changing demographic patterns. Although improvements in prevention, diagnosis, and acute treatment have reduced age-standardized mortality in many regions, the overall number of stroke cases and survivors continues to rise. Comprehensive epidemiological analysis will remain essential for healthcare planning, clinical research, pharmaceutical development, and public health policy aimed at reducing the global impact of stroke.

Key Benefits of this Report

Comprehensive analysis of global stroke incidence, prevalence, mortality, and patient populations.
Detailed assessment of demographic trends, disease burden, and regional epidemiology.
Insights into major risk factors, disease progression, and healthcare utilization.
Evaluation of epidemiological trends supporting clinical development and market planning.
Valuable resource for pharmaceutical companies, healthcare providers, researchers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Patient population assessment, epidemiology forecasting, market opportunity analysis, clinical trial planning, healthcare resource allocation, competitive intelligence, commercial strategy development, investment analysis, and public health planning.

Report Coverage

Historical epidemiological data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
Comprehensive analysis of global stroke epidemiology by stroke type, age group, gender, risk factor, disease severity, and geography
Evaluation of incidence, prevalence, mortality, diagnosed patient population, disability burden, survival trends, and epidemiological forecasts
Assessment of regional disease burden, healthcare utilization, demographic trends, and unmet medical needs
Analysis of major risk factors, population trends, epidemiological modeling, and future disease burden projections through 2035.

1. Executive Summary

1.1 Report Scope and Objectives
1.2 Key Findings
1.3 Global Stroke Epidemiology Snapshot
- 1.3.1 Incidence Overview
- 1.3.2 Prevalence Overview
- 1.3.3 Mortality and Disability Burden
1.4 Key Epidemiology Trends
1.5 Forecast Highlights (2025-2035)
1.6 Strategic Insights

2. Disease & Epidemiology Analysis

2.1 Introduction to Stroke
- 2.1.1 Definition and Clinical Overview
- 2.1.2 Disease Burden and Public Health Impact
- 2.1.3 Risk Factors and Disease Progression
2.2 Stroke Classification
- 2.2.1 Ischemic Stroke
- 2.2.2 Hemorrhagic Stroke
  - 2.2.2.1 Intracerebral Hemorrhage (ICH)
  - 2.2.2.2 Subarachnoid Hemorrhage (SAH)
- 2.2.3 Transient Ischemic Attack (TIA)
2.3 Etiology and Pathophysiology
- 2.3.1 Atherosclerosis and Large Vessel Disease
- 2.3.2 Cardioembolic Stroke
- 2.3.3 Small Vessel Disease
- 2.3.4 Genetic and Lifestyle Factors
2.4 Epidemiology Analysis
- 2.4.1 Global Incidence Analysis
- 2.4.2 Global Prevalence Analysis
- 2.4.3 Age-wise Epidemiology
- 2.4.4 Gender-wise Epidemiology
- 2.4.5 Stroke Subtype-wise Epidemiology
- 2.4.6 Mortality Analysis
- 2.4.7 Disability-Adjusted Life Years (DALYs)
- 2.4.8 Recurrence Rate Analysis
- 2.4.9 Epidemiology Forecast (2025-2035)

3. Market Dynamics

3.1 Market Overview
3.2 Market Drivers
- 3.2.1 Rising Aging Population
- 3.2.2 Increasing Burden of Cardiovascular Diseases
- 3.2.3 Growing Awareness and Early Diagnosis
- 3.2.4 Expansion of Stroke Care Infrastructure
3.3 Market Restraints
- 3.3.1 Limited Access in Low-Income Regions
- 3.3.2 High Cost of Acute Stroke Treatment
- 3.3.3 Delayed Diagnosis and Treatment
3.4 Market Opportunities
- 3.4.1 AI-Based Stroke Diagnosis
- 3.4.2 Expansion of Tele-Stroke Networks
- 3.4.3 Neuroprotective Therapies Development
- 3.4.4 Biomarker-Based Precision Medicine
3.5 Porter's Five Forces Analysis
3.6 PESTLE Analysis
3.7 Value Chain Analysis

4. Commercial & Market Access

4.1 Market Access Overview
4.2 Reimbursement Landscape
4.3 Health Technology Assessment Trends
4.4 Pricing Analysis
4.5 Patient Access Programs
4.6 Insurance Coverage Trends
4.7 Stakeholder Analysis

5. Innovation & Pipeline Landscape

5.1 Innovation Overview
5.2 Emerging Technologies
- 5.2.1 AI-Assisted Stroke Detection
- 5.2.2 Digital Therapeutics
- 5.2.3 Advanced Neuroimaging
- 5.2.4 Wearable Monitoring Devices
5.3 Pipeline Landscape
- 5.3.1 Phase I Pipeline Candidates
- 5.3.2 Phase II Pipeline Candidates
- 5.3.3 Phase III Pipeline Candidates
5.4 Pipeline Segmentation by Mechanism of Action
5.5 Pipeline Segmentation by Modality
- 5.5.1 Small Molecules
- 5.5.2 Biologics
- 5.5.3 Cell Therapies
- 5.5.4 Gene Therapies
5.6 Clinical Trial Landscape
5.7 Patent Analysis
5.8 Investment and Funding Trends

6. Treatment Landscape

6.1 Current Treatment Paradigm
6.2 Acute Stroke Management
- 6.2.1 Intravenous Thrombolysis
- 6.2.2 Mechanical Thrombectomy
- 6.2.3 Surgical Interventions
6.3 Secondary Stroke Prevention
- 6.3.1 Antiplatelet Therapy
- 6.3.2 Anticoagulant Therapy
- 6.3.3 Lipid-Lowering Therapy
- 6.3.4 Blood Pressure Management
6.4 Rehabilitation and Long-Term Care
6.5 Treatment Guidelines and Clinical Practice Trends

7. Global Stroke Epidemiology Report Size & Forecast

7.1 Global Market Overview
7.2 Historical Market Size Analysis (2021-2025)
7.3 Market Forecast (2026-2035)
7.4 Market Attractiveness Analysis
7.5 Incremental Growth Opportunities

8. Global Stroke Epidemiology Report Segmentation

8.1 By Stroke Type
- 8.1.1 Ischemic Stroke
  - 8.1.1.1. Thrombotic
  - 8.1.1.2. Embolic
- 8.1.2 Hemorrhagic Stroke
- 8.1.3 Transient Ischemic Attack
- 8.1.4 Others
8.2 By Drug Type
- 8.2.1 Thrombolytics
- 8.2.2 Antiplatelets
- 8.2.3 Anticoagulants
- 8.2.4 Antihypertensives
- 8.2.5 Others
8.3 By Treatment Type
- 8.3.1 IV Medication
- 8.3.2 Endovascular Therapy
- 8.3.3 Surgical Procedures
  - 8.3.3.1 Mechanical Thrombectomy
  - 8.3.3.2 Carotid Endarterectomy (CEA)
  - 8.3.3.3 Others
8.4 By Severity Type
- 8.4.1 Mild
- 8.4.2 Moderate
- 8.4.3 Severe
8.5 By Age-Group
- 8.5.1 Below 20 Years
- 8.5.2 20 to 50 Years
- 8.5.3 50 to 70 Years
- 8.5.4 Older than 70 Years
8.6 By End User
- 8.6.1 Hospitals
- 8.6.2 Specialty Clinics
- 8.6.3 Rehabilitation Centers
- 8.6.4 Others

9. Geographical Analysis

9.1 North America
- 9.1.1 Market Size and Growth
- 9.1.2 Epidemiology Trends
- 9.1.3 Regulatory Overview
- 9.1.4 Competitive Intensity
9.2 Europe
- 9.2.1 Market Size and Growth
- 9.2.2 Epidemiology Trends
- 9.2.3 Regulatory Overview
- 9.2.4 Competitive Intensity
9.3 Asia-Pacific
- 9.3.1 Market Size and Growth
- 9.3.2 Epidemiology Trends
- 9.3.3 Regulatory Overview
- 9.3.4 Competitive Intensity
9.4 Latin America
- 9.4.1 Market Size and Growth
- 9.4.2 Epidemiology Trends
- 9.4.3 Regulatory Overview
- 9.4.4 Competitive Intensity
9.5 Middle East & Africa
- 9.5.1 Market Size and Growth
- 9.5.2 Epidemiology Trends
- 9.5.3 Regulatory Overview
- 9.5.4 Competitive Intensity

10. Key Countries Analysis

10.1 United States
10.2 Canada
10.3 Germany
10.4 United Kingdom
10.5 France
10.6 Italy
10.7 Spain
10.8 China
10.9 Japan
10.10 India
10.11 South Korea
10.12 Australia
10.13 Brazil
10.14 Mexico
10.15 Saudi Arabia
10.16 South Africa

11. Regulatory & Policy Landscape

11.1 Regulatory Overview
11.2 Regulatory Framework in the United States (FDA)
11.3 Regulatory Framework in Europe (EMA)
11.4 Regulatory Framework in Japan (PMDA)
11.5 Regulatory Framework in India (CDSCO)
11.6 Regulatory Framework in China (NMPA)
11.7 Clinical Trial Regulations
11.8 Drug Approval Pathways
11.9 Pharmacovigilance Requirements
11.10 Healthcare Policies Affecting Stroke Management

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Competitive Benchmarking
12.3 Strategic Developments
- 12.3.1 Collaborations and Partnerships
- 12.3.2 Acquisitions and Mergers
- 12.3.3 Product Launches
- 12.3.4 Regulatory Approvals
12.4 SWOT Analysis
12.5 Competitive Positioning Matrix